Companies ›Healthcare ›SOLA.NS

SOLA.NS — NSE (India) Pharmaceuticals

Solara Active Pharma Sciences Ltd

$554,25

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

8,4 %

ROE

0,1 %

Net margin

0,0 %

Debt / equity

0,73

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Business description not yet wired for this issuer.

Business. Solara Active Pharma Sciences Ltd (SOLA.NS) is a pharmaceutical company headquartered in India that operates within the Healthcare sector. The firm is primarily listed on the National Stock Exchange of India (NSE). As specific segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in pharmaceutical activities.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

0,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning SOLA.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to SOLA.NS. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Solara Active Pharma Sciences Ltd (SOLA.NS) is a pharmaceutical company headquartered in India that operates within the Healthcare sector. The firm is primarily listed on the National Stock Exchange of India (NSE). As specific segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in pharmaceutical activities.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

### Capital Structure and Liquidity

Solara Active Pharma Sciences Ltd has a debt-to-equity ratio of 0.73, indicating a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 0.77, suggesting that it may face challenges in meeting short-term obligations with its current assets. The company's free cash flow stands at 597.4 million INR, which is lower than its operating cash flow of 2,128.2 million INR, indicating that capital expenditures have consumed a significant portion of its operating cash flow.

### Profitability and Returns

The company's profitability is modest, with a net income of 5.4 million INR and an operating income of 1,080.5 million INR. Its return on equity (ROE) is 0.05%, and return on assets (ROA) is 0.02%, both of which are below the industry median for pharmaceutical companies. These low returns suggest that the company is not effectively utilizing its equity and assets to generate profits.

### Segments and Geographic Exposure

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no detailed breakdown of geographic revenue distribution in the provided data, but the company's operations are primarily based in India, as indicated by the use of INR as the reporting currency.

### Growth Trajectory

The company's revenue for the latest reporting period is 12,837.6 million INR. While the company has a positive free cash flow, the absence of historical revenue data makes it difficult to assess its growth trajectory. The analyst estimate for revenue is aligned with the reported figure, indicating that the company is meeting market expectations.

### Risk Factors

The company faces a medium liquidity risk, as its current ratio is below 1, and it has a negative net cash position after accounting for total debt. The risk of dilution is assessed as low, with no significant dilution potential identified in the basic shares outstanding. The company's capital structure includes a long-term debt of 7,960.8 million INR, which could pose a refinancing risk if interest rates rise.

### Recent Events

The most recent financial data available is from the latest market data filing, which includes the company's revenue and profitability figures. There are no additional filings or transcripts provided that would indicate recent strategic changes or operational developments.

Key takeaways

Solara Active Pharma Sciences Ltd has a moderate level of leverage with a debt-to-equity ratio of 0.73.
The company's liquidity position is medium, with a current ratio of 0.77.
Profitability is weak, with a net income of 5.4 million INR and low ROE and ROA.
The company's revenue is concentrated in a single business segment, with no detailed geographic breakdown.
The company has a positive free cash flow but faces potential liquidity challenges due to its current ratio and net cash position.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$554,25

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$10.94B

Net cashⓘ

-$7.96B

Current ratioⓘ

0.8

Debt / equityⓘ

0.7

ROAⓘ

0.0%

ROEⓘ

0.1%

Cash conversionⓘ

39411.0%

CapEx / revenueⓘ

-3.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin8,4 %Above median

Net Margin0,0 %Below median

ROE0,1 %Below median

Capex / Rev-3,1 %Above median

D/E0,73Bottom quartile

Cash Conv394,11Best in class

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Solara Active Pharma Sciences Ltd Market data — financials · 2026-05-29
Solara Active Pharma Sciences Ltd Market data — analyst estimates · 2026-05-29

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

SOLA.NSCanonical

NSE (India) · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread